Katelyn Queen

Katelyn Queen

Auto-generated profile, based on publicly available information

Katelyn Queen

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Open access
PDF file
AAAngel Arizpe
Angel Arizpe
Carol Y OchoaCarol Y Ochoa
Carol Y Ochoa
SNStephanie Navarro
Stephanie Navarro
SKSue E. Kim
Sue E. Kim
KQKatelyn Queen
Katelyn Queen
AFAlbert Farias
Albert Farias
Background: Discrimination is associated with worse mental and physical health outcomes. However, the associations among cancer survivors are limited. Objective: We examined whether discrimination is associated with HRQoL and whether adjusting for it reduces racial/ethnic disparities in HRQoL among cancer survivors. Methods: Cross-sectional data from adult cancer survivors who completed surveys on discrimination in the medical settings (DMS), everyday perceived discrimination (PD), and HRQoL in the “All of Us” Program from 2018 to 2022 were assessed. We created a binary indicator for fair-to-poor vs. good-to-excellent physical health and mental health. PD and DMS scores were a continuous measure with higher scores reflecting more discrimination. Multivariable logistic regression models tested whether DMS and PD are associated with HRQoL and whether they differently affect the association between race/ethnicity and HRQoL. Results: The sample (N = 16,664) of cancer survivors was predominantly White (86%) and female (59%), with a median age of 69. Every 5-unit increase in DMS and PD scores was associated with greater odds of fair-to-poor physical health (DMS: OR [95%CI] = 1.66 [1.55, 1.77], PD: 1.33 [1.27, 1.40]) and mental health (DMS: 1.57 [1.47, 1.69], PD: 1.33 [1.27, 1.39]). After adjusting for DMS or PD, Black and Hispanic survivors had a decreased likelihood of fair-to-poor physical health and mental health (decrease estimate range: − 6 to − 30%) compared to White survivors. This effect was greater for Black survivors when adjusting for PD, as the odds of fair-to-poor mental health compared to White survivors were no longer statistically significant (1.78 [1.32, 2.34] vs 1.22 [0.90, 1.64]). Conclusion: Experiences of discrimination are associated with lower HRQoL and reducing it may mitigate racial/ethnic disparities in HRQoL.

11 November 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
AAAngel Arizpe
Angel Arizpe
TCTiffany M. Chapman
Tiffany M. Chapman
CRClaudia Rodriguez
Claudia Rodriguez
ACAlberto Carvajal
Alberto Carvajal
KQKatelyn J. Queen
Katelyn J. Queen
AFAlbert Farias
Albert Farias
Background: Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex. Methods: Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors. Results: In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences. Conclusions: Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities. Impact: The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.

2 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KQKatelyn A. Queen
Katelyn A. Queen
ACAlisa Cario
Alisa Cario
CBChristopher L. Berger
Christopher L. Berger
JSJason Stumpff
Jason Stumpff
Kinesins support many diverse cellular processes, including facilitating cell division through mechanical regulation of the mitotic spindle. However, how kinesin activity is controlled to facilitate this process is not well understood. Interestingly, post-translational modifications have been identified within the enzymatic region of all 45 mammalian kinesins, but the significance of these modifications has gone largely unexplored. Given the critical role of the enzymatic region in facilitating nucleotide and microtubule binding, it may serve as a primary site for kinesin regulation. Consistent with this idea, a phosphomimetic mutation at S357 in the neck- linker of KIF18A alters the localization of KIF18A within the spindle from kinetochore microtubules to peripheral microtubules. Changes in localization of KIF18A-S357D are accompanied by defects in mitotic spindle positioning and the ability to promote mitotic progression. This altered localization pattern is mimicked by a shortened neck-linker mutant, suggesting that KIF18A-S357D may cause the motor to adopt a shortened neck-linker like state that prevents KIF18A from accumulating at the plus-ends of kinetochore microtubules. These findings demonstrate that post-translational modifications in the enzymatic region of kinesins could be important for biasing their localization to particular microtubule subpopulations.

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
JJJames D. Joseph
James D. Joseph
KSKatherine Schutt
Katherine Schutt
Kira FisherKira Fisher
Kira Fisher
KQKatelyn Queen
Katelyn Queen
OBOlivia Budington
Olivia Budington
FAFred Aswad
Fred Aswad
Background: Chromosome instability (CIN), characterized by frequent and ongoing loss or gain of chromosome number, is commonly observed in tumor cells. Although long recognized as a vulnerability of cancer cells, potential CIN-selective therapeutic targets have only recently been discovered. Genetic studies from multiple groups have identified the mitotic kinesin, KIF18A, as selectively essential for the proliferation of CIN and aneuploid cells. By targeting KIF18A genetically and with novel small molecule inhibitors here we present data supporting KIF18A as therapeutic target in CIN tumors. Methods and Materials: To explore the therapeutic potential of KIF18A, we evaluated the effects of KIF18A genetic depletion and small molecule inhibition in both CIN-positive and CIN-negative cell lines. Biochemical, cell proliferation and phenotypic assays were used to characterize the potency and cellular activity of reference and novel KIF18A small molecule inhibitors. Anti-tumor activity of KIF18A inhibitors was assessed in CIN-positive cell line xenograft models. Results: In triple negative breast and colorectal CIN positive cancer cell lines siRNA mediated KIF18A knockdown and small molecule inhibition of the KIF18A ATPase activity both lead to a reduction in proliferation associated with an increase in mitotic index and multi-polar spindles. Consistent with KIF18A knockdown, KIF18A inhibition results in increased spindle length and chromosome alignment defects. Importantly, these effects are not observed with KIF18A knockdown or KIF18A inhibition in non-transformed, near diploid cells. In vivo, treatment of CIN-positive xenograft tumors with potent, novel KIF18A inhibitors results in robust anti-tumor activity with minimal impact on body weight. Conclusions: Collectively our data support KIF18A as a therapeutic target and provide rationale for the continued development of potent selective small molecule KIF18A inhibitors for the treatment of CIN positive cancers. Citation Format: James D. Joseph, Katherine Schutt, Kira Fisher, Katelyn Queen, Olivia Budington, Weifeng Mao, Wei Liu, Zhengqing Zhu, Xiangping Zhang, Yisong Xiao, Kunmin Lai, Xiaohui Gu, Jason Stumpff, Fred Aswad. Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4965.

16 June 2026
Verified
Dataset
Closed access
KQKatelyn Queen
Katelyn Queen
KAKevin Abuhanna
Kevin Abuhanna
PSPaul Spellman
Paul Spellman
A series of functions to generate a pedigree around a given person with a known genetic mutation, based on US census data. Pedigree will also track mutation status of all members. Pedigree is built down to children, back to grandparents, and out to cousins. There is also a function to generate pedigrees without genetic mutations.

1 December 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
AAAngel Arizpe
Angel Arizpe
Carol Y OchoaCarol Y Ochoa
Carol Y Ochoa
KQKatelyn Queen
Katelyn Queen
AFAlbert Farias
Albert Farias
Purpose: We assessed the association between discrimination (medical setting and perceived) and health-related quality of life (HRQoL) and explored whether perceived racial discrimination modifies these associations in a sample of cancer survivors. Methods: We analyzed responses from cancer survivors collected from May 2018 to July 2022 from the “All of Us” program. Discrimination in the medical setting (DMS) was measured using the 7-item scale, and perceived discrimination (PD) was assessed using the Everyday Discrimination 9-item scale. Scaled with increments of 5 units, continuous scores were created from both DMS(range: 0-5.6) and PD(0-9) measures where higher scores represented greater DMS/PD experiences. HRQoL, dependent variables, was assessed using the PROMIS-10 Global Health survey, where the sub-scale measured physical health (PH) and mental health (MH). Binary indicators were created for low PH (<42) and low MH (<40) using PROMIS’s t-values. Multivariable adjusted (age, sex, ethnicity/race, nativity, SES barriers, racial discrimination type, and treatment status) logistic models tested the associations between 1) PD and HRQoL, 2) DMS and HRQoL, and 3) explored whether perceived racial discrimination modified these relationships. Results: The median age in our sample (n=8892) was 67 years (IQR=19.9) and had median DMS and PD scores of 1(SD: 1.6) and 0.6(1), respectively. The sample was predominately White race (90.5%) and female (64%). Survivors who reported low PH (n=888) had a median score of 1(1.4) for DMS and 1.6(2) for PD. Among those with low MH (n=786), the median score for DMS was 1(1.4), and for PD was 1.8(2). Multivariable-adjusted models showed that for every 5-unit increase in the DMS score, there was an 85%(OR=1.85, 95%CI:1.66-2.08) and 66%(1.66, 1.48-1.86) increase in the likelihood for low PH and MH, respectively. Similarly, every 5-unit increase in PD was associated with a 30%(1.30, 1.21-1.40) and 28%(1.28, 1.19-1.38) increase likelihood of low PH and MH, respectively. We found significant interaction terms, indicating that discrimination due to race modified the relationship between DMS and MH, and PD and MH (pinteractionDMS=0.02, pinteractionsPD<0.01). For every 5-unit increase in DMS and PD, among those who reported discrimination due to race, DMS and PD were associated with a 33%(1.33, 1.03-1.77) and 8%(1.08, 0.93-1.13) increase in odds of low MH, respectively. However, only statistical significance was reached for DMS (p<0.001). Conclusion: Our study highlights that DMS has a negative impact on the MH of cancer survivors, especially for those indicating discrimination due to race. To improve survivors' HRQoL, healthcare systems, and policymakers need to address DMS by promoting inclusivity and equity at the societal and healthcare levels. Citation Format: Angel Arizpe, Carol Y. Ochoa-Dominguez, Katelyn Queen, Albert J. Farias. Discrimination in the medical setting is negatively associated with health-related quality of life for cancer survivors: Findings from an All of Us cross-sectional study [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B119.